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Objective. To assess the prevalence, clinical and laboratory characteristics, and short-term outcomes of poststroke hip fracture (HF).
Methods. A cross-sectional study of 761 consecutive patients aged ≥60 years (82.3 ± 8.8 years; 75% females) with osteoporotic HF.
Results. The prevalence of poststroke HF was 13.1% occurring on average 2.4 years after the stroke. The poststroke group compared
to the rest of the cohort had a higher proportion of women, subjects with dementia, history of TIA, hypertension, coronary artery
disease, secondary hyperparathyroidism, higher serumvitamin B12 levels (>350 pmol/L), walking aid users, and living in residential
care facilities. The majority of poststroke HF patients had vitamin D insufficiency (68%) and excess bone resorption (90%). This
group had a 3-fold higher incidence of postoperative myocardial injury and need for institutionalisation. In multivariate analysis,
independent indicators of poststroke HF were female sex (OR 3.6), history of TIA (OR 5.2), dementia (OR 4.1), hypertension (OR
3.2), use of walking aid (OR 2.5), and higher vitamin B12 level (OR 2.3). Only 15% of poststroke patients received antiosteoporotic
therapy prior to HF. Conclusions. Approximately one in seven HFs occurs in older stroke survivors and are associated with poorer
outcomes. Early implementation of fracture prevention strategies is needed.
1. Introduction
Stroke and osteoporotic hip fracture (HF) are two highly
prevalent conditions among the elderly, both with poor clin-
ical outcomes and high medical and social costs. Worldwide
the prevalence of these events is expected to increase dra-
matically because of rapid population ageing. Osteoporosis
and low-impact trauma are the main determinants of HF
in the elderly. Stroke increases the risk of falls [1–5] as a
result of impaired locomotor function and muscle weakness
[6, 7], accelerates bone loss (especially in the hemiplegic
leg) [8–26], and subsequently leads to fractures [4, 27–29].
Although accumulating evidence suggests bidirectional links
between vascular diseases, including stroke, and osteoporotic
fractures [9–11, 30–35], there is still considerable uncertainty
regarding the contribution of stroke to osteoporotic HF.
The incidence of HF after a stroke was reported to be 1.5–
4 times [27, 29, 36, 37] or even >7 times [28] higher than in
the general population, but this was not observed in other
studies [38–40]. Similarly, the reported prevalence of previ-
ous stroke among patients with HF ranges from 3% to 38.5%
[4, 41–43].
Data concerning clinical characteristics, outcomes, pre-
diction, and prevention of poststrokeHF are also inconsistent
[3, 35, 41, 44, 45]. Most previous studies have examined only
a small number of the many clinical and pathogenic factors
involved in stroke andHF.The exact aetiology and pathogen-
esis of poststroke osteoporosis remain not fully understood.
Studies have generally focused on bone mineral density
(BMD) and documented accelerated bone loss, especially in
paretic limbs [10, 12–14, 22], with only few analysing mineral
and bone metabolism in poststroke patients [15, 21, 46, 47].
Fracture prevention and osteoporosis care are not included
in current guidelines for stroke management.
The aims of this study were (1) to investigate the preva-
lence of poststrokeHF, (2) to compare inHFpatientswith and
without a previous stroke the demographic, clinical, and lab-
oratory characteristics and short-term outcomes, (3) to test in
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both groups the associations of parameters related to mineral
and bone metabolism, and (4) to determine whether any
clinical or laboratory characteristics are indicative/predictive
for a poststroke HF.
2. Materials and Methods
2.1. Study Patients. A total of 847 consecutive patients aged
60 years and older who were admitted to the Canberra Hos-
pital with low-traumaHF and underwent surgery were inves-
tigated. After the exclusion of 86 patients with pathological
HF (metastatic bone cancer, multiple myeloma, and Paget’s
disease) or primary hyperparathyroidism, a total of 761
patients (570 women and 191 men) were included in the anal-
ysis. All patients or their guardians gave informed consent
to undergo examination and surgical treatment. The study
was conducted according to the Helsinki Declaration and
approved by the regionalHumanResearchEthicsCommittee.
2.2. Clinical Data Collection. The data were collected pro-
spectively: demographic, medical, lifestyle, and residential
characteristics, and in-hospital management, peri-operative
complications and short-term outcomes were recorded. In all
patients a detailed medical history and full physical exami-
nation were performed. The presence of comorbidities was
identified based on clinical manifestations, review of hospital
medical records, general physician’s progress notes/letters,
and medication used. Data on a history of previous stroke
and transient ischaemic attack (TIA) were initially abstracted
from the medical records. A patient was included in the
group with a history of stroke if he met the following criteria:
(1) presence of neurological deficit consistent with a stroke
and/or (2)medical documentation confirming a stroke before
the HF.
Short-term outcomemeasures included (1) postoperative
myocardial injury as defined by cardiac troponin I rise (cTnI
> 0.06 𝜇g/L), (2) prolonged length of stay (LOS ≥ 20 days),
(3) discharge to a permanent residential care facility (RCF)
for patients who were admitted from home, and (4) all-cause
in-hospital death.
2.3. Sample Collection and Methods of Laboratory Analyses.
In each patient venous blood and second morning urine
samples were collected under standardised conditions after
a 12-hour overnight fast usually within 24 hours after arrival
at the emergency department. After centrifugation of blood,
one serum sample as well as the urine sample was frozen and
stored at −70∘C until further analysis. Routine haematolog-
ical and biochemical assessments were performed by stan-
dardized methods on autoanalyzers at the day of collection.
All patients had the following tests performed: complete
blood count, urea, creatinine and electrolytes, liver func-
tion tests, fasting blood glucose (and HbA1C in diabetic





cated), C-reactive protein (CRP), and cTnI (two-step chemi-
luminescent microparticle immunoassay, Chemiflex, Abbott
Labs, Mississauga, Ontario, Canada). Glomerular filtration
rate (eGFR) was calculated using a standardized serum
creatinine-based formula normalized to a body surface area
of 1.73m2 [48]. Full blood count, urea, creatinine and electro-
lytes, serumcTnI, andCRPwere also assessedwithin 24hours
postoperatively and then after if clinically indicated.
In order to evaluate mineral and bone metabolism in
all patients, the following biochemical parameters were
determined: serum concentrations of 25(OH) vitamin D
(25(OH)D), intact PTH, total calcium, phosphate, magne-
sium, osteocalcin (OC), and bone-specific alkaline phospha-
tise (BAP) asmarkers of bone formation and urinary concen-
trations of deoxypyridinoline (DPD/Cr), and cross-linkedN-
telopeptide of type 1 collagen (NTx/Cr) as markers of bone
resorption (both corrected for urinary creatinine concentra-
tions in the same sample). Serum 25(OH)D was measured by
radioimmunoassay kit (Dia Sorin, Stillwater, MN, USA; sen-
sitivity 0.7 nmol/L) and intact PTH by two-site chemilu-
minescent enzyme-linked immunoassay on DPC Immulite
2000 (Diagnostic Products Corp, Los Angeles, CA, USA; sen-
sitivity 0.07 pmol/L). Serum OC was determined by electro-
chemiluminescent immunoassay (Elecsys 1010, Roche Diag-
nostics, Ltd. Corp., IN, USA), serum BAP by Metra BAP
ELISA (Quidel Corp., San Diego, CA, USA), urinary NTx
by ELISA (Wampole Labs, Princeton, NJ, USA), and urinary
DPD by 2-site chemiluminescent enzyme-labelled immuno-
assay (DPC Immulite 2000, Diagnostic Products, Los Ange-
les, CA, USA). All samples were analysed with commercially
available kits of the same lot number according to the manu-
facturer’s protocol and blind to any clinical information. In
these methods both the intra- and interassay coefficient of
variations (CVs) ranged from 2.1% to 12.7%. Serum calcium
concentrations were corrected for serum albumin.
For the analyses, insufficiency of vitamin D was defined
as 25(OH)D < 50 nmol/L and deficiency as 25(OH)D <
25 nmol/L based on current recommendations. Secondary
hyperparathyroidism (SHPT) was defined as elevated serum
PTH (>6.8 pmol/L, the upper limit of the laboratory reference
range). For levels of bone turnovermarkers, we used the stan-
dard laboratory reference ranges and data provided by the
manufacturer. In the analyses chronic kidney disease (CKD)
was defined as eGFR < 60mL/min/1.73m2 (CKD stage ≥
3). To express the balance between bone formation and
resorption, the data of biochemical bone turnover markers
were evaluated as 𝑍-scores, and a bone balance status index





was the patient’s value of a marker
and 𝑋 and SD were the normal mean and standard devia-
tions for this parameter, respectively. For BSI the formula was
BSI = (𝑍-scores of OC + BAP)/2 − (𝑍-scores of DPD/Cr +
NTx/Cr)/2.
2.4. Statistical Analyses. Descriptive statistics included
means and standard deviations (SD) for continuous variables
or percentages for categorical variables. Comparisons
between groups were performed using analysis of variance
and Student’s 𝑡-test (for continuous variables) and 𝜒2 test
(for categorical variables). Pearson’s correlation coefficient
with log-transformed data (to achieve normal distribution)
was used to study the correlation between variables; Bonfer-
roni and Sidak adjustments for multiplicity have been
performed. Univariate and multivariate linear regression
Stroke Research and Treatment 3
analyses were performed to determine the associations
between different parameters related to mineral and bone
metabolism in patients with and without history of stroke;
all potential confounding variables (demographic, clinical,
and biochemical) with statistical significance ≤0.20 on
univariate analyses were included in multivariate analysis.
The relationships between presence of poststoke HF and clin-
ical characteristics as well as different laboratory parameters
as independent variables were investigated by linear regres-
sion analyses. To quantify the significance ofmulticollinearity
phenomena in regression analysis, the variance inflation
factor was calculated. Two-sided 𝑃 < 0.05 values were con-
sidered statistically significant. The Stata software version 10
(StataCorp, College Station, TX, USA) was used for all sta-
tistical analyses.
3. Results
3.1. Prevalence and General Clinical Characteristics of Patients
with Poststroke Hip Fracture. Of 761 older HF patients, 100
(13.1%) had a history of stroke, of whom 83.0% were women.
The clinical characteristics of the patients according to stroke
history are summarized in Table 1. HF occurred on average
2.4 ± 2.6 years after the stroke, in 68.0% on the hemiplegic
side. Among poststroke HF patients, the proportion of
females and individuals admitted from long-term residential
care facilities (RCF) was significantly higher compared to the
rest of the cohort. The predominance of women was not age
related, as the age of women andmen with poststroke HF did
not differ, whereas in the nonstroke group females were sig-
nificantly older (+2.1 year, 𝑃 = 0.002). As would be expected,
the group of poststroke HF patients has a higher prevalence
of previous TIAs, dementia, hypertension, coronary artery
disease (CAD), and myocardial infarction, American Society
of Anaesthesiologists score ≥3 on admission, and using
a walking device; atrial fibrillation was also more often
among the poststroke patients, but the difference did not
reach statistical significance. History of stroke was inversely
related with male gender (Pearson correlation coefficient
𝑟 = −0.151; 𝑃 = 0.011) and positively associated with hyper-
tension (𝑟 = 0.186, 𝑃 = 0.002) and CAD (𝑟 = 0.128, 𝑃 =
0.033).The two groups did not differ with regard tomean age,
HF type, prevalence of diabetes mellitus, chronic obstruct-
ive pulmonary disease, Parkinson’s disease, chronic kidney
disease, alcohol consumption, and smoking habits.
Among 24 haematological and biochemical variables,
including parameters of iron metabolism, vitamin B12, folic
acid, liver, renal and thyroid functions, only mean values
of leukocyte count and serum concentration of vitamin B12
were higher, and the mean corpuscular volume was lower in
poststroke HF patients compared to the rest of the cohort
(Table 2).
The prevalence of anaemia (haemoglobin < 120 g/L:
32.0% versus 36.7%, 𝑃 = 0.456), renal impairment (eGFR <
60mL/min/1.73m2: 47.0% versus 4.3.4%, 𝑃 = 0.650), hypo-
albuminemia (<33 g/L: 32.0% versus 27.9%, 𝑃 = 0.637), low
total lymphocyte count (<12 × 109: 40.0% versus 44.7%,
𝑃 = 0.548), low transferrin (<1.5 g/L: 33.0% versus 25.9%,
𝑃 = 0.356), and low vitamin B12 levels (<250 pmol/L: 33.0%
versus 40.8%, 𝑃 = 0.395) was similar in both groups. In other
wards, about one-third of HF patients with or without history
of stroke were anaemic and undernourished, and nearly half
have renal impairment (CKD stage ≥ 3).
On the other hand, the proportion of subjects with
higher vitamin B12 levels (>350 pmol/L) was significantly
higher among the poststroke HF patients (60.0% versus
39.4%, 𝑃 = 0.032), although none of the patients had solid
or haematological malignancies, serious liver diseases, or
received parenteral nutrition, which might have been asso-
ciated with elevated vitamin B12 serum levels [51–53].
3.2. Mineral and Bone Metabolism in Poststroke Hip Fracture
Patients. History of stroke was associated with higher levels
of serum PTH (Pearson correlation coefficient 𝑟 = 0.155,
𝑃 = 0.010), vitamin B12 (𝑟 = 0.139, 𝑃 = 0.027), urinary bone
resorptionmarker DPD/Cr (𝑟 = 0.183, 𝑃 = 0.004), and lower
BSI (𝑟 = −0.170, 𝑃 = 0.009). In the poststroke group com-
pared to the rest of the cohort (Table 3), the mean serum
PTH levels (+34.3%) and the incidence of SPTH (+15.8%)
were significantly higher, although themean serum25(OH)D
concentrations were similar, and the incidence of vitamin D
insufficiency (<50 nmol/L) was even slightly lower (−13.7%,
𝑃 = 0.044). Interestingly, among the poststroke patients
56.0% of those with 25(OH)D < 50 nmol/L had SHPT,
whereas in the nonstroke group elevated PTH was observed
only in 36.0% of subjects with vitamin D insufficiency (𝑃 =
0.007, 𝜒2 test), indicating that in the former group in addition
to low vitamin D levels other mechanisms contribute to the
excess of PTH. In an age- and sex-adjusted model, serum
PTH levels were significantly associatedwith history of stroke
(OR = 1.058, 95%CI 1.00–1.11, 𝑃 = 0.025) indicating that
risk for poststroke HF relative to 1 pmol/L increase in PTH
increases by 5.8%. Of note, the proportion of subjects with
SHPT among HF patients without CVDwas 23.2%.The odds
ratio (adjusted for sex, age, dementia, 25(OH)D < 50 nmol/L,
andDPD/Cr> 7.5 nmol/𝜇mol) for SHPT in the poststrokeHF
subjects compared to the later group was 4.34 (95%CI 1.63–
11.52, 𝑃 = 0.003).
The mean serum concentrations of calcium (albumin
corrected), phosphate, and magnesium were within normal
ranges and similar in both groups. Regarding bone turnover
status, compared to the rest of the cohort, patients with
poststroke HF demonstrated a lower mean serum level
of osteocalcin and higher mean levels of urinary bone
resorption markers DPD/Cr (𝑃 = 0.004) and NTx/Cr
(𝑃 = 0.056) resulting in a significantly higher nega-
tive BSI (resorption exceeds formation). The mean serum
OC/BAP ratio, an indicator of osteoblastic differentiation
[54], in the poststroke HF patients was also significantly
lower. DPD/Cr was elevated (>7.5 nmol/𝜇mol) in 90.0.0% of
poststroke patients, in 81.9% of the total nonstroke group
and in 74.8% of the non-CVD group. NTx/Cr was ele-
vated (>65 nmol/𝜇mol) in 78.0%, 71.6%, and 70.4%, respec-
tively; osteocalcin was below the low limit of normal range
(<14 ng/mL) in 57.0%, 51.9%, and 50.1%, respectively. In
multiple regression analyses adjusted for age, sex, HF type,
25(OH)D, PTH, eGFR, calcium, phosphate, and magne-
sium, history of stroke was an independent determinant of
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Table 1: Sociodemographic and clinical characteristics in older hip fracture patients with and without history of stroke.
Characteristics HF poststroke (𝑛 = 100) HF without history of stroke (𝑛 = 661) 𝑃 value
Age, years (mean ± SD) 84.1 ± 7.72 81.9 ± 7.96 0.120
Age, females, years (mean ± SD) 84.1 ± 8.03 82.5 ± 7.59 0.264
Age, males, years (mean ± SD) 83.3 ± 4.92 80.4 ± 8.62 0.521
Females, % 83.0 70.0 0.011
Admitted from long-term RCF, % 50.0 26.9 0.004
Cervical/trochanteric HF, 𝑛 55/45 346/315 0.698
Coronary artery disease, % 35.0 20.9 0.002
Previous myocardial infarction, % 10.0 4.6 0.024
Hypertension, % 60.0 42.1 0.001
Atrial fibrillation, % 18.0 12.5 0.092
TIA, % 16.0 6.1 0.001
Dementia, % 47.0 26.4 0.001
Diabetes mellitus, % 19.0 16.8 0.479
COPD, % 13.0 11.1 0.583
Parkinson’s disease, % 3.0 4.6 0.473
eGFR < 60mL/min/1.73m2, % 47.0 43.4 0.650
eGFR < 30mL/min/1.73m2, % 7.9 4.5 0.371
ASA score ≥3, % 96.9 68.2 0.001
Current Smoker, % 6.0 5.3 0.785
Ex-smoker, % 12.0 9.1 0.365
∗Alcohol overuser, % 5.0 5.6 0.795
User of walking device, % 50.0 32.2 0.001
HF: hip fracture; RCF: residential care facility; TIA: transient ischaemic attack; eGFR: estimated glomerular filtration rate; ASA: American Society of
Anaesthesiologists; COPD: chronic obstructive pulmonary disease. ∗Three or more times per week.
both higher DPD/Cr levels (𝛽 = 3.87, 95%CI 1.11–6.64,
𝑃 = 0.006) and lower BSI (𝛽 = −4.17, 95%CI −7.29–1.06,
𝑃 = 0.027).
In the total cohort, higher B12 levels (>350 pmol/L) were
associated with significantly lower mean serum OC/BAP
ratio (0.63 ± 0.45 versus 0.78 ± 0.65, 𝑃 = 0.036) and serum
albumin concentrations (36.0 ± 6.5 versus 38.2 ± 5.7 g/L,
𝑃 = 0.003). Poststroke patients with higher vitamin B12 levels
had significantly higher BAP levels (28.4 ± 10.9 versus 21.0 ±
6.0 IU/L, 𝑃 = 0.028). Compared to nonstroke subjects, the
poststroke group with higher vitamin B12 levels had a lower
OC/BAP ratio (0.54 ± 0.36 versus 0.65 ± 0.47, 𝑃 = 0.025).
3.3. Metabolic Relationships in Hip Fracture Patients with
and without History of Stroke. The relationships between
parameters of mineral and bone metabolism in HF patients
with and without history of stroke were further analysed by
Pearson correlation coefficients, and the results are displayed
in Table 4. These demonstrate similarities as well as remark-
able differences between the groups. In both groups, therewas
a significant negative correlation between log-transformed
serum PTH levels and calcium, calcium correlated positively
with osteocalcin, serumphosphate levelswere associated pos-
itively with urinary DPD/Cr and negatively with eGFR, BAP
correlated with vitamin B12, osteocalcin correlated negatively
with eGFR, which inversely correlated with phosphate and
age, the two urinary resorption markers were significantly
interrelated, and both strongly correlated to BSI. However,
only in poststroke HF patients, serum phosphate levels
correlated positively with serum calcium, osteocalcin, and
urinary NTx/Cr and negatively with BSI, and PTH correlated
with vitamin B12 levels. No associationwas observed between
25(OH)D concentrations and any of bone turnover markers
and BSI in the poststroke group, while in the nonstroke group
25(OH)D inversely correlated with each of the four bone
markers and positively with BSI (all 𝑃 < 0.03, not shown).
3.4. Clinical and Laboratory Variables Independently Associ-
ated with History of Stroke in Older Hip Fracture Patients. In
multiple regression models, poststroke HF was designated as
the dependent variable and all clinical, and laboratory char-
acteristics with𝑃 ≤ 0.20 on univariate analysis were designed
as the independent variables (Table 5). Amultivariate logistic
regression model which included only clinical characteristics
revealed that the six following variables were independent
indicators for history of stroke in HF patients: female sex,
history of TIA, dementia, hypertension, CAD, and use of
a walking aid. The mean variance inflation factor (VIF) of
1.19 indicates that multicollinearity was not significant in this
model.
When the laboratory parameters were analysed as con-
tinuous variables and adjusted for age and sex, the significant
independent associations with poststroke HF showed only
vitamin B12 (𝑃 = 0.006), DPD/Cr (𝑃 = 0.035), and female sex
(𝑃 = 0.011). In a similar model with laboratory parameters
as categorical variables corrected for age and sex, higher
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Table 2: Haematologic, renal, liver, and thyroid parameters in older hip fracture patients with and without history of stroke.
Characteristics HF poststroke HF without history of stroke 𝑃 value
Erythrocyte count, ×1012/L 4.21 ± 0.61 4.08 ± 0.61 0.217
Haemoglobin, g/L 126.0 ± 18.9 124.7 ± 16.9 0.601
Leukocyte count, ×109/L 12.0 ± 4.22 10.5 ± 4.24 0.034
Lymphocyte count, ×109/L 1.24 ± 1.39 1.31 ± 1.22 0.742
MCV, fl 87.4 ± 16.5 90.8 ± 5.98 0.019
MCH, pg/cell 30.3 ± 3.35 30.7 ± 2.29 0.290
MCHC, g/L 338.0 ± 19.4 340.7 ± 37.1 0.660
RDW, % 15.1 ± 2.05 15.2 ± 9.53 0.942
Iron, 𝜇mol/L 4.81 ± 4.12 5.33 ± 4.39 0.507
Transferrin, g/L 1.68 ± 0.49 1.72 ± 0.48 0.582
Transferrin saturation, % 11.08 ± 10.07 11.65 ± 8.36 0.716
Ferritin, mg/L 313.1 ± 244.9 298.9 ± 283.3 0.778
Vitamin B12, pmol/L 482.6 ± 321.0 376.0 ± 256.0 0.027
Folic acid (serum), nmol/L 25.2 ± 16.7 26.1 ± 15.4 0.747
Urea, mmol/L 7.9 ± 4.30 7.8 ± 3.67 08.37
Creatinine, mmol/L 92.0 ± 43.86 93.6 ± 57.24 0.873
eGFR, mL/min/1.73m2 62.5 ± 25.2 64.9 ± 23.2 0.561
Albumin, g/L 36.6 ± 6.0 37.0 ± 6.4 0.723
Bilirubin, 𝜇mol/L 13.0 ± 5.95 12.2 ± 7.62 0.503
ALT, U/L 20.4 ± 12.8 21.4 ± 22.3 0.801
ALP, U/L 103.8 ± 44.3 105.9 ± 85.8 0.882
GGT, U/L 55.8 ± 90.5 54.3 ± 98.6 0.928
TSH, 𝜇U/L 1.25 ± 1.47 1.60 ± 2.31 0.361
T4, pmol/L 16.02 ± 3.61 15.98 ± 3.54 0.949
CRP, mg/L 137.1 ± 76.7 129.2 ± 83.1 0.583
The values are expressed asmean± standard deviation (SD).HF: hip fracture;MCV:mean corpuscular volume;MCH:mean corpuscular haemoglobin;MCHC:
mean corpuscular haemoglobin concentration; RDW: red-cell distribution width; eGFR: estimated glomerular filtration rate; ALT: alanine aminotransferase;
ALP: alkaline phosphatase; GGT: gamma glutamyltransferase; TSH: thyroid-stimulating hormone; T
4
: total thyroxin.
Table 3: Parameters of mineral and bone metabolism in older hip fracture patients with and without history of stroke.
Parameter Poststroke HF Without stroke HF 𝑃 value
Serum calcium∗, mmol/L 2.27 ± 0.12 2.28 ± 0.13 0.730
Serum phosphate, mmol/L 0.89 ± 0.30 0.96 ± 0.50 0.428
Serum magnesium, mmol/L 0.77 ± 0.12 0.78 ± 0.13 0.887
25(OH)vitamin D, nmol/L 40.1 ± 20.05 36.8 ± 17.97 0.319
PTH, pmol/L 9.0 ± 6.66 7.6 ± 5.41 0.019
Osteocalcin, ng/L 13.8 ± 8.44 18.0 ± 16.18 0.025
BAP, IU/L 25.5 ± 9.76 26.8 ± 14.97 0.624
Osteocalcin/BAP ratio 0.59 ± 0.37 0.78 ± 0.78 0.026
Urinary DPD/Cr, nmol/𝜇mol 16.0 ± 14.02 12.0 ± 5.53 0.004
Urinary NTx/Cr, nmol/𝜇mol 207.9 ± 279.0 149.7 ± 141.3 0.056
BSI −12.5 ± 14.8 −8.6 ± 6.1 0.009
PTH > 6.8 pmol/L, % 50.0 34.2 0.046
25(OH)D < 50 nmoL/L, % 68.0 81.7 0.044
25(OH) vitamin D < 25 nmol/L, % 27.0 31.0 0.626
Osteocalcin < 14.0 ng/L, % 57.0 51.9 0.582
BAP < 14.0 IU/L, % 11.0 9.3 0.734
Urinary DPD/Cr > 7.5 nmol/𝜇mol,% 90.0 81.9 0.189
Urinary NTx/Cr > 65 nmol/𝜇mol, % 78.0 71.6 0.444
The values are expressed as mean ± standard deviation (SD) or percentage.
∗Adjusted for serum albumin. PTH: parathyroid hormone; BAP: bone specific alkaline phosphate; DPD/Cr: deoxypyridinoline corrected for urinary creatinine
concentration; NTx/Cr: cross-linked N-telopeptide of type 1 collagen corrected for urinary creatinine concentration; BSI: bone balance status index.
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Table 4: Pearson correlation coefficients among selected parameters of mineral and bone metabolism and their relation to age and renal
function in older hip fracture (HF) patients with and without history of prefracture stroke.
Poststroke HF HF without history of stroke
𝑟 𝑃 𝑟 𝑃
Calcium-PTH −0.328 0.047∗ −0.273 <0.001
Calcium-osteocalcin 0.3226 0.052∗ 0.139 0.034∗
Calcium-BAP 0.137 0.434 0.16 0.015
Osteocalcin-eGFR −0.525 0.001 −0.346 <0.001
Calcium-eGFR −0.464 0.004 −0.075 0.250
DPD/Cr-NTx/Cr 0.779 <0.001 0.380 <0.001
DPD/Cr-BSI −0.926 <0.001 −0.690 <0.001
NTx/Cr-BSI −0.952 <0.001 −0.876 <0.001
Age-eGFR −0.443 0.005 −0.337 <0.001
Phosphate-calcium 0.415 0.011 0.055 0.399
Phosphate-DPD/Cr 0.580 0.001 0.208 0.003
Phosphate-osteocalcin 0.489 0.002 0.123 0.061
Phosphate-BAP 0.215 0.216 0.169 0.01
Phosphate-NTx/Cr 0.478 0.006 0.079 0.263
Phosphate-BSI −0.531 0.003 −0.109 0.126
Phosphate-eGFR −0.32 0.054∗ −0.173 0.008
PTH-vitamin B12 0.365 0.028∗ 0.016 0.817
BAP-vitamin B12 0.442 0.009 0.188 0.006
Values for all variables other than age were log transformed before analysis.
PTH: parathyroid hormone; eGFR: estimated glomerular filtration rate; DPD/Cr: urinary deoxypyridinoline corrected for urinary creatinine concentration;
NTx/Cr: cross-linked N-telopeptide of type 1 collagen corrected for urinary creatinine concentration; BSI: bone balance status index. ∗Nonsignificant (𝑃 >
0.005) correlations when Bonferroni and Sidak adjustments for multiplicity were adopted.
Table 5: Clinical and laboratory characteristics independently associated with poststroke hip fracture.
Characteristic Model 1 Model 2 Model 3
OR 95% CI 𝑃 value OR 95% CI 𝑃 value OR 95% CI 𝑃 value
Female sex 3.73 1.11–12.59 0.034 3.64 1.17–11.42 0.026 3.58 1.03–12.45 0.045
TIA 5.17 1.62–16.48 0.005 5.17 1.59–16.79 0.006
Dementia 4.16 1.56–11.05 0.004 4.14 1.79–9.59 0.001
Hypertension 3.34 1.37–8.14 0.008 3.20 1.29–7.91 0.012
CAD 2.70 1.03–7.07 0.043 2.41 0.97–5.97 0.057
Use of walking aid 2.20 1.03–5.09 0.043 2.47 1.08–5.65 0.032
Vitamin B12 > 350 pmol/L 2.35 1.05–5.49 0.039 2.33 1.03– 5.25 0.042
𝑅
2 0.221 0.126 0.225
Mean V1F 1.19 1.25 1.03
OR: odds ratio; CI: confidence interval; TIA: transient ischaemic attack; CAD: coronary artery disease; VIF: variance inflation factor.
Model 1 (clinical parameters) adjusts for age, sex, dementia, hypertension, CAD, history of myocardial infarction, TIA: atrial fibrillation, renal impairment
(eGFR < 60mL/min/1.73m2), use of walking aid, and living in a long-term residential care facility.
Model 2 (laboratory parameters) adjusts for age, sex, vitamin D insufficiency (25(OH)D <50 nmol/L), elevated PTH (>6.8 pmol/L), and high bone resorption
markers (DPD/Cr > 7.5mmol/𝜇mol, NTX/Cr > 65mmol/𝜇mol).
Model 3 (combined clinical and laboratory parameters) adjusts for al variables in Models 1 and 2.
vitamin B12 levels and female sex were the only significant
independent indicators of history of stroke (Table 5, Model
2). The other variables identified in the univariate analysis
dropped out of themodel, presumably because of their strong
correlations with these two factors.
In multiple regression analysis using both clinical and
categorical laboratory characteristics as independent vari-
ables, all clinical factors as well as higher serum vitamin
B12 levels retained substantial independent value for post-
stroke HF, except CADwhich becomes borderline significant
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(𝑃 = 0.057). Of note, relation of higher serum vitamin
B12 to poststroke HF in the final model adjusted for both
clinical and laboratory confounding variables did not change.
This suggests that higher levels of B12, in contrast to vitamin
D insufficiency, SHPT, and excess bone resorption, contain
information not captured in and complementary to clinical
characteristics. The mean variance inflation factor (VIF) of
1.03 in the finalmodel indicates thatmulticollinearity was not
significant.
3.5. Predicting Poststroke Hip Fracture. To examine which
parameters could be clinically useful for assessing the risk
of poststroke HF, we evaluated the predictive properties of
all variables independently associated with poststroke HF as
well as of SPTH (a significant independent determinant when
subjects with history of stroke are compared with patients
without CVD) and living in a permanent RCF (although not
an independent but a significant and practically important
indicator of poststroke HF). The relative risk (RR) estimates
of characteristics associated with poststroke HF are depicted
in Figure 1. Among elderly HF patients, risk of having a
poststroke HF is greater 3.7 times in subjects with history
of TIA and in permanent RCF residents, 3.2 times higher in
females, 2.9 times in patients with dementia or hypertension,
2.2 times in those with SHPT, 2.1 times in subjects with higher
serum vitamin B12 (>350 pmol/L), 2 times in patients with
CAD, and 1.8 times in walking aid users. The sensitivity of
these variables ranges between 83% (female sex) and 16%
(TIAhistory, RCF resident) and the specificity between 90.5%
(TIA history) and 30.0% (female sex), positive predictive
value between 17% (female sex)—45.2% (TIA history, SHPT,
and RCF resident) and 60% (vitamin B12 > 350 pmol/L), and
negative predictive value between 79.1% (SHPT) and >90%
(female sex, hypertension, and vitamin B12 > 350 pmol/L).
The probability of poststroke HF increases, understand-
ably, when two or more factors coexist. Measurement of
serum PTH and vitamin B12 may provide additional prog-
nostic information when results are combined with selected
clinical factors. The highest RR demonstrates the following
combinations: dementia and TIA (RR = 5.9), TIA and higher
vitamin B12 level (RR = 5.4), dementia and hypertension
(RR = 5.1), dementia and higher vitamin B12 level (RR
= 4.4), and TIA and SHPT (RR = 3.1). The specificity of
each of the pairs of variables shown in Figure 1 is 93% or
higher, and the negative predictive value is >88.0%, while
the sensitivity ranges only between 13.3% and 39.5%, and the
positive predictive value ranges between 40.0% and 71.4%.
3.6. Short-Term Outcomes in Poststroke Hip Fracture Patients.
Data summarised in Table 6 shows that, in HF patients,
history of stroke was associated with 2.7 higher incidence
of postoperative myocardial injury defined as cTnI rise and
being discharge to a long-term RCF but did not influence
significantly the length of hospital stay (LOS) and the in-
hospital mortality (5.0% versus 4.8% in subjects with and
without history of stroke, resp.).
In the total cohort, SHPT was an independent predictor



















Figure 1: Estimated relative risk and 95% confidence intervals (CI)
for poststroke hip fracture in older persons by selected clinical
and laboratory characteristics. 1—use of a walking aid; 2—coronary
artery disease (CAD); 3—serum vitamin B12 > 350 pmol/L; 4—
elevated serum PTH level (<6.8 pmol/L); 5—hypertension; 6—
dementia; 7—female sex; 8—resident of a long-term care facility; 9—
history of transient ischaemic attack; 10—CAD and serum vitamin
B12 > 350 pmol/L; 11—hypertension and serum vitamin B12 >
350 pmol/L; 12—CAD and use of a walking aid; 13—CAD and
hypertension; 14—use of awalking aid and elevated serumPTH level
(<6.8 pmol/L); 15—transient ischaemic attack and elevated serum
PTH level (<6.8 pmol/L); 16—dementia and use of a walking aid;
17—dementia and female sex; 18—transient ischaemic attack and
hypertension; 19—dementia and serum vitamin B12 > 350 pmol/L;
20—dementia and hypertension; 21—transient ischaemic attack and
serum vitamin B12 > 350 pmol/L; 22—transient ischaemic attack
and dementia.
Table 6: Effect of history of stroke on short-term outcomes in older
hip fracture patients.
Outcome OR 95% CI 𝑃 value
Postoperative myocardial injury∗ 2.68 1.31–5.47 0.007
LOS ≤ 10 days 0.92 0.44–1.90 0.816
LOS ≥ 20 days 1.35 0.66–2.77 0.413
New discharges to long-term
RCF 2.69 1.11–6.54 0.028
In-hospital death 1.07 0.23–5.00 0.927
Adjusted for age and sex.
∗Cardiac troponin I rise (>0.06𝜇g/L). LOS: length of hospital stay.
was present in all subjectswhodied, in 65.8%withmyocardial
injury, in 71.7% with prolonged hospital stay (>20 days), and
in 73.2%discharged to a long-termRCF (all𝑃 < 0.01).Higher
vitamin B12 levels (>350 pmol/L) in the total cohort were also
associated with in-hospital death (OR = 7.33, 95%CI 1.57–
34.14,𝑃 = 0.011) and prolonged LOS (OR = 1.98, 95%CI 1.16–
3.37, 𝑃 = 0.012). Higher vitamin B12 levels had all poststroke
HF patients who died and 71.4% with prolonged LOS (𝑃 =
0.027).
3.7. Prefracture Use of Antiosteoporotic Therapy by Poststroke
Hip Fracture Patients. Compared to the rest of the cohort in
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the poststrokeHF group, the prefracture use of a bisphospho-
nate (15.0% versus 8.5%) and supplementation with vitamin
D (15.0% versus 9.3%) and calcium (21.0% versus 11.0%) were
slightly but not significantly higher (all 𝑃 > 0.1) and far from
adequate.
4. Discussion
4.1. Main Findings. This cross-sectional analysis of data
from an observational, prospective study demonstrates a
high prevalence of poststroke in elderly subjects among HF
patients (1), describes the differences in the clinical profile,
mineral-bone metabolism characteristics, and short-term
outcomes in poststroke compared to nonstroke HF patients
(2), emphasises the prefracture underuse of antiosteoporotic
therapy (3), and presents prognostic indicators of having a
poststroke HF (4). While some of our findings corroborate
previous work, others are novel and will be discussed inmore
detail.
4.2. Prevalence and Clinical Profile. We found that among
761 consecutive older patients with osteoporotic HF, the
prevalence of poststrokeHFwas 13.1%; it occurred on average
2.4 years after the stroke and in 68% of patients on the side of
hemiplegia. Our findings on stroke prevalence are consistent
with most reported data showing that stroke account for
7.3% to 15.3% of all HFs [35, 41, 43, 45], but higher than
3.9% in some studies [55] and lower than 38.5% in 1997 in
a Swedish study [4]. Such differences might be attributable
to age (our cohort was approximately 11 years older than the
Swedish study: 84.1 versus 73 years, resp.), incidence rates of
stroke survivors, environmental factors, and activity levels.
Our data are in agreement with observations that most HFs
occurred ipsilateral to the side of hemiplegia within 2-3 years
after the stroke [4, 28, 30, 35, 37]. In concordance with other
studies, we did not find differences between the poststroke
and nonstroke groups with regard to patient age [35, 37], type
of HF [35], smoking history, alcohol consumption, diabetes,
AF [27], Parkinson’s disease, COPD, and renal impairment
nor most (22 of 25) routine laboratory parameters.
The poststroke HF patients demonstrated a number of
clinical and laboratory characteristics different from those in
the rest of the cohort. The poststroke group showed a female
predominance (independent of age), higher proportion of
subjects living in long-term RCF, using walking aids, with
dementia, having a history of TIA, hypertension, CAD,
prior myocardial infarction, and ASA score ≥ 3. Among
25 laboratory parameters, higher serum vitamin B12 levels,
leukocyte count, and lowermean corpuscular volume (MCV)
in poststroke subjects were the only variables differing the
groups. Our results are consistent with most previous reports
of up to a 4-fold female predominance among poststroke
HF persons [4, 25, 27, 28, 37, 45, 56], despite the age-
specific incidence rates of stroke in women being lower than
in men [57]. Only one study found a prevalence of men
among poststroke HF patients [35]. Living in institutions
[4], dementia [4], and ASA score ≥ 3 [35] is known to
be associated with poststroke HF. The associations of TIA,
hypertension, and CAD, established risk factors for stroke,
with osteoporotic fractures [58–65] have also been docu-
mented. Our observations extend findings noted by others by
providing data on a population with poststroke HF.
Anunexpected findingwas highermean vitaminB12 con-
centrations in the poststrokeHF patients, while theMCVwas
lower, and all other erythrocyte-related parameters were sim-
ilar in both groups, suggesting the significant contribution of
multiple factors (blood loss, inflammation, andmalnutrition)
other than vitamin B12 on erythropoiesis and haemoglobin
status. Serum vitamin B12 levels were positively associated
with history of stroke in crude and multivariate adjusted
models irrespective of whether vitamin B12 was treated as a
continuous or categorical variable (>350 pmol/L). Although
some previous studies suggested that vitamin B12 deficiency
by causing increased homocysteinaemia is a risk factor for
osteoporosis and fragility fractures [66–71], recurrent stroke,
vascular dementia, and Alzheimer’s disease, existing data
are inconclusive [72–76]. A reduction in HF rates in elderly
Japanese stroke patients with residual hemiplegia treatedwith
mecobalamine and folate was reported [68]. However, in
general, causal relationships of low levels of vitamin B12
with reduced bone quality [77–80] and developing dementia
[81, 82] are currently not supported. In poststroke patients
no favourable effects of treatment with vitamin B12 (plus
folic acid and vitamin B6) on risk of recurrent stroke, carotid
intima-media thickness, myocardial infarction, or death have
been observed [83–86]. Moreover, elevated vitamin B12
serum levels were associated, especially in the elderly, with
symptomatic venous thromboembolism following major
orthopaedic surgery of the low limb [87], mortality [88–90],
carcinomas, haematological malignancies, and parenteral
nutrition [51–53]. Vitamin B12 therapy increased cardiovas-
cular risk in patients with diabetic neuropathy [91], cancer
outcomes, and all-cause mortality in patients with CAD [92].
To the best of our knowledge, ours is the first study to show
an association between higher vitamin B12 serum levels and
poststroke HF. Understanding the underlying mechanisms
will be a future research area of great interest.
4.3. Mineral and Bone Metabolism. With respect to indices
of mineral and bone metabolism, we found that vitamin
D insufficiency and excessive bone resorption were highly
prevalent in both groups, but the poststroke group showed
significantly higher mean levels of serum PTH and urinary
bone resorption markers, lower values for osteocalcin, osteo-
calcin/BAP ratio, and amore pronounced imbalance between
bone resorption and formation with resorption significantly
exceeding formation.
These results are in line with reports showing (1) a high
prevalence of hypovitaminosis D and SHPT in poststroke
patients [15, 69, 93–97] and HF patients [98–100], (2) an
association of vitamin D insufficiency and especially elevated
serum PTH levels with cardiovascular disease [31, 101–111]
including stroke [69, 93, 112], hypertension [94, 104, 113–124],
CAD [125], and carotid artery intima-media thickness (IMT)
[126, 127], and (3) a high prevalence of osteoporosis in stroke
patients [128] and a negative balance between bone formation
and resorption in poststrokeHF subjects [15–17, 21, 46, 47, 93,
129, 130].
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Other researchers, however, reported no association
between vitamin D status and stroke risk [131, 132], between
PTH and blood pressure/hypertension [116, 118, 133] and
between PTH and IMT [134]. In some studies, poststroke
patients demonstrated significant BMD loss, while serum
PTH and vitamin D levels and bone turnover markers were
within normal range [26].
Not surprisingly, altered vitamin D and PTH levels,
two pleiotropic factors with multiple physiological functions
in calcium homeostasis, morphogenesis, cell proliferation,
differentiation, and apoptosis, affect both bone and vascular
health [135, 136].The role of PTH as an indicator of poststroke
HF deserves additional comment to avoid misinterpreta-
tion. In this study of HF subjects, serum PTH levels were
associated with an increased risk of poststroke HF in a
continuous fashion after adjusting for age and sex. The mean
PTH levels and prevalence of SHPT were significantly higher
in poststroke patients compared to the rest of the cohort
(despite similarmean 25(OH)D levels and even slightly lower
prevalence of hypovitaminosis D), and elevated PTH levels
independently predicted history of stroke when comparison
was made with patients without CVD but not with all
nonstroke patients among which a significant proportion
had CVD. These findings are in agreement with previous
studies reporting that higher serum PTH levels are associated
with stroke, hypertension, CAD, AF, and congestive heart
failure [31, 69, 101, 106, 107, 109, 110, 125, 137–140]. PTH
receptors have been found on cardiomyocytes [141] and
endothelial cells [142, 143]. Serum PTH levels were shown
to be an independent risk factor for cardiovascular events,
cardiovascular mortality, and all-cause mortality, even in
individuals with PTH within the normal range [109, 137, 140,
144, 145]. Altogether these data support the hypothesis that
elevated PTH concentration is an abnormality of mineral
metabolism affecting both the skeleton and vascular system
(particularly the function ofmedium- and large-sized arteries
and the myocardium), and therefore the presence of even
mild PTH elevation is a condition that should be taken into
account for the prevention of both CVD and fracture risks.
Although vitamin D deficiency is known as the main
cause of SHPT, clinical practice shows that the vitamin
D-PTH relationship is complex. In elderly patients with
long-standing hemiplegic stroke, hypovitaminosis D occurs
without hyperparathyroidism [15, 16, 93] possibly because of
immobilization-induced hypercalcaemia which may inhibit
the compensatory PTH elevation; no correlation between
serum calcium and PTH concentrations was seen in these
patients [97]. In contrast, we found in poststroke HF subjects
higher mean PTH levels and a higher SHPT prevalence
despite similar mean 25(OH)D concentration and slightly
lower prevalence of hypovitaminosis D compared to the
nonstroke group, as well as a significant correlation between
serum calcium and PTH levels in both groups. Taken
together, these data indicate that the group of poststroke
patients is clinically and biologically heterogeneous and in
addition to hypovitaminosis D other factors attributable to
SHPT must be taken into consideration.
In both groups no significant correlation between mark-
ers of bone turnover, except urinary markers of bone
resorption, was present suggesting an imbalance between
resorption and formation. However, uncoupling of these
two processes, as indicated by the BSI index, was more
prominent in the poststroke patients. Consistent with pre-
vious studies [47], we found that excess bone resorption
in poststroke HF patients was near universal. Increased
sclerostin production by osteocytes in response to skeletal
unloading/immobilization has been proposed as an impor-
tant molecular mechanism for acceleration of bone remod-
elling, with bone resorption exceeding formation [46, 146].
Reports on association between CVD and bone turnover
markers are inconsistent [147, 148]. Increased bone resorption
(high DPD) has been shown to be an independent predictor
of CVD, including stroke [31, 33], and decreased bone
formation, measured by bone histometry, was independently
associated with increased coronary calcification [149].
Compared to the rest of the cohort, in poststroke HF
patients, the mean BAP serum levels did not differ, but
the mean OC concentration and the ratio OC/BAP were
significantly lower. These may suggest impaired osteoblastic
maturation, as BAP is expressed in the early period of
osteoblastic differentiation, whereas OC is expressed in the
later period [150]. This abnormality was associated with
higher vitamin B12 levels. Indeed, vitamin B12 positively
correlated with BAP in both groups, but patients with higher
vitamin B12 levels had significantly lower mean OC/BAP
ratio compared to those with vitamin B12 < 350 pmol/L. The
poststroke subjects with higher vitamin B12 concentrations
had significantly higher BAP levels and the lowest OC/BAP
ratio, indicating that vitamin B12 may influence maturation
of osteoblasts, which in turn may contribute to bone fragility
and fractures. In vitro, vitaminB12 in low concentrations dose
dependently increased alkaline phosphatase (ALP) activity of
osteoblastic cells [151], while vitamin B12 deficiency did not
affect the onset of osteoblast differentiation, maturation, and
matrix mineralization [152] and had no influence on ALP
expression in human osteoblasts [153] but increased homo-
cysteine induced osteoclastogenesis in a dose-dependent
manner [152]. These data indicates that vitamin B12 defi-
ciency (when causing hyperhomocysteinaemia)may increase
osteoclast formation and bone resorption, while higher B12
levels may affect osteoblast maturation. Reduction in serum
OC/BAP ratio is associated with vertebral fractures indepen-
dent of BMD in diabetic men [54]. In our study, vitamin
B12 levels correlated with PTH. It appears, therefore, that
higher serum B12 levels among poststroke HF patients in
addition to SHPT and excess bone resorption may in part
mediate the link between stroke and HF. The multivariate
logistic regression analysis showed that higher serum vitamin
B12 level was associated with poststroke HF independently of
parameters of mineral and bone metabolism indicating that
bone remodelling status, including osteoblast dysfunction, is
incorporated in themodel; this suggests that vitamin B12 is an
important regulator of bone cell function and higher serum
vitamin B12 levels may be directly linked to bone fragility in
poststroke HF.
The next interesting finding of the study relates to phos-
phate homeostasis. As in other studies [47], the mean serum
concentrations of calcium (albumin corrected), phosphate,
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and magnesium were within normal ranges and similar in
both groups. However, upon classification of patients into
two groups, with and without history of stroke, Pearson
correlation results differed significantly. In the group with
poststroke HF, serum phosphate level, though within the
normal range, significantly and positively correlated with
serum calcium and bone formation marker osteocalcin, as
well as with both urinary bone resorption markers (DPD/Cr
and NTx/Cr) and negatively with BSI. In the nonstroke
group phosphate correlated positively only with BAP and
DPD/Cr. In poststroke subjects, even small increases in
phosphatemia are associated with increased bone resorption
and decreased BSI, despite higher serum osteocalcin and
calcium concentrations, both of which are negatively asso-
ciated with eGFR. Notably, the phosphate levels correlated
positively with in-hospital death. Even small increments in
serum phosphate have been found to be associated with
arterial calcification [154], adverse cardiovascular, and renal
events and mortality [107, 155–158]. In the light of the above,
our observation that, in the poststroke HF subjects, higher
phosphate levels (without hyperphosphatemia) are associated
with BSI, bone resorption markers, and osteocalcin, which
also exerts a profound effect on energymetabolism [159, 160],
can be interpreted as an additional factor contributing to the
link between vascular dysfunction/calcification, subsequent
stroke, and HF. However, whether higher phosphate levels
(within the normal range) are directly implicated in the
pathogenesis of poststroke HF or merely reflect mineral and
bone metabolism status warrants further clarification.
Among several specific biological mechanisms that may
underlie these associations of particular interest are fibroblast
growth factor 23 (FGF-23) and Klotho proteins. FGF-23, an
osteocytes-derived circulating hormone, that controls serum
levels of phosphate, 1,25-dihydroxy vitamin D3, and PTH,
interacts with RAAS [161] and may, therefore, affect both the
cardiovascular system and skeleton. Elevated FGF-23 levels
contribute to decreased 1,25-dihydroxy vitamin D3 levels
[162], secondary hyperparathyroidism [163], suppression of
osteoblast differentiation, and matrix mineralization in vitro
and in vivo [122] and are associatedwith vascular calcification
[157, 164], endothelial dysfunction [165, 166], cardiovascular
disease [167], mortality [163, 167, 168], HF, and nonvertebral
fractures in elderly men [169]. However, in some studies
[170, 171] the relationship between FGF-23 and vascular
calcification was not observed.
Our results further support the link between mineral-
bone metabolism abnormalities and stroke (and other CVD)
and demonstrate that some metabolic interactions, partic-
ularly between phosphate and bone resorption markers,
between vitamin B12 and OC/BAP ratio, are prevalent in
poststroke HF subjects. Circulating 25(OH)D, PTH, phos-
phate, and vitaminB12 levels are linked to both stroke andHF,
further accentuating their important underlying role in vas-
cular and bone biology.
Our final multivariate regression analysis demonstrated
that six clinical characteristics (female sex, history of TIA,
dementia, hypertension, CAD, and use of a walking aid) and
higher serum B12 level are independent indicators/predictors
for the development of HF. Because hypovitaminosis D was
near universal among the HF patients, regardless history of
stroke, and it is only one of the determinants of SHPT, it did
not appear as an independent indicator of poststroke HF in
our model.
4.4. Clinical Applications: Outcomes, Prediction, and Preven-
tionTherapies. This study demonstrates that compared to the
rest of the cohort, poststroke HF patients had approximately
a 3-fold higher incidence of postoperative myocardial injury
(as evidenced by cardiac troponin I rise) and need to be
discharge to a long-term RCF. Our observations regarding
the discharge status are consistent with some studies [4], but
not others [35]. Similarly, in agreement with some [35] but
not all [4, 172] previous reports, we found that in-hospital
mortality [35] and LOS did not differ significantly between
patients with and without history of stroke. Of note, SHPT
and higher vitamin b12 levels were associatedwith in-hospital
death and duration of hospital stay.
Approximately one in 7 older stroke survivors will suffer
a HF which is associated with serious short- and long-term
health consequences. To design preventive strategies, it is
important to identify which persons are at the greatest risk.
Our data suggests that comparedwith nonstrokeHF patients,
the relative risk of poststroke HF is 1.8–3.7 times higher in
females, subjects with history of TIA, dementia, hyperten-
sion, CAD, using a walking aid, living in a permanent RCF,
and having SHPTor higher vitamin B12 levels (>350 pmol/L).
Presence of any two of these characteristics increases the RR
to 2.5–5.9. SHPT and higher vitamin B12 levels are promising
biomarkers for identification of older adults at increased risk
of poststroke HF, and their measurement provides additional
prognostic information when combined with clinical factors.
These findings suggest that the combined effect of having a
stroke, being a female and one of the above mentioned con-
ditions, might significantly contribute to and predict an HF.
It should, however, be pointed out that, in general, the
specificity of analysed factors was higher than the sensitivity,
and the negative predictive value (usually above 88%) was
higher than the positive predictive value with exception for
female sex and hypertension which have sensitivity of 83%
and 76.3%, respectively. That means that these two factors
identifymore poststroke persons at risk forHF, while the pro-
bability that the complication will not occur is low only when
any of the studied characteristics is not present. Antiosteo-
porotic therapy for stroke survivors has not been adopted
into current guidelines and routine clinical practice possibly
because accurate predictive indicators were not available.
Although the prognostic tools for poststrokeHF need further
improvement, the above-listed factors may be helpful in
evaluating the risk of developing HF and deciding who is
most likely to benefit from intervention.
Only a small proportion of our poststroke patients (15%)
received antiosteoporotic medications prior to their HF. In
concordance with our observations, use of bisphosphonates
was low (2.1%–2.7%) and did not differ between poststroke
and nonstroke groups in other countries [30, 36]. Many HF
are preventable, and the effectiveness of antiresorptive agents
and vitamin D in fracture risk reduction in stroke survivors
has been demonstrated [24, 96, 97, 173–175], but the gap
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between existing evidence-based and actual care remains
huge. The results of this study in keeping with previous
reports [56, 176] emphasise the importance of assessment
for and prevention of poststroke osteoporosis and falls.
Currently recommended measures in addition to bisphos-
phonates, vitamin D, and calcium supplementation include
sunlight exposure [177], improving physical activity, exercises
aimed at preventing falls [178–181], and hip protectors [182,
183]. In poststroke patients with immobilization-induced
hypercalcaemia, calcitonin (in combination with vitamin D)
may be helpful [97, 184]. Antiosteoporosis medications are
generally safe and well tolerated, but the extraskeletal risks
of bisphosphonates and calcium supplements, although rare,
should also be considered [185–187]. To date there have been
no studies on the use of bone anabolic agents (PTH 1–34,
teriparatide), strontium ranelate, or denosumab in stroke
survivors.
It should be emphasized that CVDs, especially history
of TIA, hypertension, and CAD, are not only important
and modifiable hazards to the brain but also independent
indicators/predictors of poststoke HF. Therefore, correction
of hypovitaminosisD and SHPT, which plays a specificmech-
anistic role in the pathogenesis of osteoporosis and CVD,
and adequate antiosteoporotic therapy in addition to anti-
hypertensive, antithrombotic, and cholesterol lowering treat-
ment may markedly contribute to both stroke and fracture
prevention. Our data supports reports challenging the exist-
ing approach to homocysteine lowering with vitamin B ther-
apy and suggests a need to consider the association of
higher serum vitamin B12 levels and adverse effects in
stroke patients. Although the serum B12 level below which
total homocysteine and methylmalonic acid levels become
elevated is 400 pmol/L [188], we found that the serumvitamin
B12 concentration > 350 pmol/L is associated with adverse
clinical outcomes. Vitamin B therapy may thus be beneficial
in persons with B12 deficiency but may be harmful when the
serum B12 concentration is higher (even within the reference
range), especially in subjects with impaired renal function.
Over recent decades, stroke mortality was falling, and
the population of stroke survivors was steadily increasing.
To reduce the public health burden of the substantial pro-
portion of poststroke subjects with HF secondary prevention
programs directed on progression of osteoporosis should be
included in the guidelines for management of these patients.
5. Limitations
Our study has several limitations. First, owing to the cross-
sectional study design, causal effects cannot be determined.
Second, in this single-centre study there were only 100
poststroke HF patients; therefore, its statistical power might
be insufficient for detecting all relationships. Third, serum
levels of ionized calcium, 1,25(OH)2D, FGF-23, and Klotho
were not examined, and the dietary phosphorus and calcium
intake were not assessed, although these variables contribute
to mineral-bone metabolism and can provide additional
insights to underlying mechanisms. Fourth, the cohort was
comprised predominantly of Caucasians, and the findings
may not be applicable to other racial groups.The strengths of
this study include a comprehensive assessment of a relatively
large well-characterized cohort of consecutive older patients
with osteoporotic HF representative of real-life practice and
consideration of multiple potential biologic factors, some of
which have not been studied extensively previously.
6. Conclusions
In the elderly, approximately one in seven HF occurs in
stroke survivors, usually within the first 2.4 years after the
stroke. PoststrokeHFs are prevalent inwomen and associated
with dementia, history of TIA, hypertension, CAD, hypovi-
taminosis D, SHPT, high bone resorption, higher serum vita-
min B12 levels, and poorer outcomes (postoperative myocar-
dial injury and RCF need). In stroke survivors prefracture
antiosteoporotic therapy is rarely used; early implementation
of fracture prevention strategies is urgently needed.
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